David J. Schlanger, Executive Chairman and Director of Progyny, Inc. (NASDAQ:PGNY), filed a Form 4 on November 9, 2026, disclosing the exercise of stock options and subsequent sale of a combined 164,608 shares of common stock across two transaction dates, November 5 and November 9, 2026.
Key Highlights
- Option exercises: Schlanger exercised stock options covering 3,400 shares on November 5, 2026, and 161,208 shares on November 9, 2026, both at an exercise price of $0.91 per share.
- Shares sold on November 5: 3,400 shares were sold at a weighted average price of $35.2209, in multiple transactions ranging from $35.00 to $35.32.
- Shares sold on November 9: 161,208 shares were sold at a weighted average price of $35.7263, in multiple transactions ranging from $35.00 to $35.99.
- Rule 10b5-1 plan: According to the filing, both sales were made pursuant to a Rule 10b5-1 trading plan entered into on July 2, 2026.
- Remaining beneficial ownership: Following all reported transactions, Schlanger directly held 238,462 shares of common stock.
- Remaining options: After the exercises, Schlanger's directly held stock options with an exercise price of $0.91 and an expiration date of August 3, 2027, totaled 67,620.
Schlanger's November 2026 Option Exercises and Plan-Based Sales at Progyny
According to the filing, David J. Schlanger, identified as Executive Chairman and Director of Progyny, Inc., reported two sets of transactions under Table I and Table II of the Form 4. On November 5, 2026, Schlanger exercised options covering 3,400 fully vested shares of common stock at an exercise price of $0.91 per share, bringing his direct holdings to 241,862 shares. He then sold those 3,400 shares at a weighted average price of $35.2209, reducing his direct holdings to 238,462 shares.
On November 9, 2026, Schlanger exercised an additional 161,208 fully vested options at the same exercise price of $0.91, raising his direct holdings to 399,670 shares before the corresponding sale. He subsequently sold the 161,208 shares at a weighted average price of $35.7263, returning his direct common stock holdings to 238,462 shares. The filing notes that the November 9 sales occurred in multiple transactions at prices ranging from $35.00 to $35.99.
The filing states that both sales were executed pursuant to a Rule 10b5-1 trading plan that Schlanger entered into on July 2, 2026. The options exercised on both dates are described in the filing as "fully vested and exercisable," with an expiration date of August 3, 2027. The filing was signed by Mark Livingston as Attorney-in-Fact on November 9, 2026.
What Was Disclosed
Progyny Executive Chairman David J. Schlanger disclosed the exercise of 164,608 stock options at $0.91 and the sale of an equal number of common shares across November 5 and November 9, 2026, all under a pre-established Rule 10b5-1 trading plan dated July 2, 2026.




Please wait processing your request...